Physician profile
Thomas Eickmann
NPI 1801840491
$145,093.91
in general payments reported to CMS, 2019-2025
26 companies · $6,614 in 2025
The $6,614 reported for 2025 was more than what 85% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $39K · 2021: $7,060 · 2022: $7,973 · 2023: $46K · 2024: $21K · 2025: $6,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $43K · Royalty Or License: $18K · Travel and Lodging: $9,719 · Food and Beverage: $2,523 · Education: $36.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $43,225.00 |
| Royalty Or License | $18,084.01 |
| Travel and Lodging | $9,719.23 |
| Food and Beverage | $2,523.20 |
| Education | $36.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyocera Medical Technologies, INC. | $119,560.94 | 2020-2025 | |
| Renovis Surgical Technologies, INC. | $16,633.38 | 2019 | |
| Aesculap Implant Systems, LLC | $7,470.32 | 2019-2020 | |
| Depuy Synthes Sales INC. | $348.97 | 2019-2024 | Fms, Healix Knotless Peek, Na |
| Arthrex, INC. | $286.19 | 2021-2023 | Arthrex |
| Gemini Mountain Medical, LLC | $169.70 | 2024 | |
| Medical Device Business Services, INC. | $119.01 | 2021-2024 | Velys |
| Encore Medical, Lp | $113.80 | 2019 | |
| Stryker Corporation | $64.59 | 2020-2023 | Bio4 |
| Acumed LLC | $46.16 | 2022 | |
| Ferring Pharmaceuticals INC. | $46.05 | 2021-2025 | Euflexxa |
| Pacira Therapeutics, INC. | $44.01 | 2020 | |
| Next Science LLC | $39.72 | 2025 | Blastx, Xperience |
| Ossur Americas, INC. | $30.84 | 2024 | Miami J |
| Zimmer Biomet Holdings, INC. | $25.96 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $22.00 | 2025 | Evos |
| Heraeus Medical, LLC. | $21.32 | 2022 | |
| Heron Therapeutics, INC. | $18.47 | 2021 | |
| Fidia Pharma USA INC. | $18.35 | 2022 | |
| Abbott Laboratories | $14.13 | 2021 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$658,997.10 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Eickmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.